Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash & Equivalents (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Cash & Equivalents for 4 consecutive years, with $50.8 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 87.14% to $50.8 million in Q3 2025 year-over-year; TTM through Sep 2025 was $50.8 million, a 87.14% decrease, with the full-year FY2024 number at $383.2 million, up 199.32% from a year prior.
  • Cash & Equivalents was $50.8 million for Q3 2025 at Centessa Pharmaceuticals, up from $44.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $544.5 million in Q1 2022 to a low of $44.2 million in Q2 2025.
  • A 4-year average of $253.1 million and a median of $171.5 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: soared 199.32% in 2024, then crashed 87.14% in 2025.
  • Centessa Pharmaceuticals' Cash & Equivalents stood at $393.6 million in 2022, then plummeted by 67.48% to $128.0 million in 2023, then skyrocketed by 199.32% to $383.2 million in 2024, then crashed by 86.74% to $50.8 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Cash & Equivalents are $50.8 million (Q3 2025), $44.2 million (Q2 2025), and $105.2 million (Q1 2025).